Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 9 Multiple Myeloma 7 Glioma 6 Neoplasm Metastasis 5 Lymphoma 5 Hematologic Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Neurofibromatosis 1 4 Pancreatic Neoplasms 3 Neoplasms 3 Colorectal Neoplasms 3 Thyroid Neoplasms 2 Neurofibroma, Plexiform 2 Lung Neoplasms 2 Leukemia, Myelomonocytic, Juvenile 2 Glioblastoma 2 Brain Neoplasms 2 Astrocytoma 2 Uveal Melanoma 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thyroid Cancer, Papillary 1 Stomach Neoplasms 1 Sarcoma 1 Refractory Differentiated Thyroid Gland Carcinoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1

Interventions

Doxorubicin 13 Specimen Handling 12 pembrolizumab 11 Magnetic Resonance Spectroscopy 10 Biopsy 10 Cyclophosphamide 9 X-Rays 7 Ifosfamide 7 Radiotherapy 6 Phantoms, Imaging 6 Gemcitabine 6 liposomal doxorubicin 5 Nivolumab 5 tazemetostat 4 palbociclib 4 fludarabine 4 atezolizumab 4 Temozolomide 4 Radiation 4 Nuclear Medicine Department, Hospital 4 Irinotecan 4 larotrectinib 3 cabozantinib 3 Surveys and Questionnaires 3 Ipilimumab 3 Carboplatin 3 Bevacizumab 3 ulixertinib 2 tipifarnib 2 selpercatinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × trametinib × 90 days × Clear all

NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡